Cytochalasin E is a mycotoxin actin polymerization inhibitor initially produced by species of Aspergillus. Cytochalasin E increases levels of IL-8, ICAM-1, and CD-54 in vitro. Cytochalasin E also exhibits anticancer chemotherapeutic and anti-angiogenic activities. In endothelial cells, cytochalasin E inhibits cell proliferation and FGF-stimulated angiogenesis. In similar animal models, this compound inhibits lung tumor growth.
| Cas No. | 36011-19-5 |
|---|---|
| Purity | ≥98% |
| Formula | C28H33NO7 |
| Formula Wt. | 495.57 |
| Melting Point | 206°C (dec) |
| Appearance | White Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C9882 Info Sheet PDF |
|---|
Ikewaki N, Yamada A, Inoko H. Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the HeLa epithelial cell line. Microbiol Immunol. 2003;47(10):775-83. PMID: 14605444.
Udagawa T, Yuan J, Panigrahy D, et al. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth. J Pharmacol Exp Ther. 2000 Aug;294(2):421-7. PMID: 10900214.
Gan Y, Au JL, Lu J, et al. Antiproliferative and cytotoxic effects of geldanamycin, cytochalasin E, suramin and thiacetazone in human prostate xenograft tumor histocultures. Pharm Res. 1998 Nov;15(11):1760-6. PMID: 9834000.
